The closing price of Novabay Pharmaceuticals Inc (AMEX: NBY) was $0.10 for the day, down -5.86% from the previous closing price of $0.11. In other words, the price has decreased by -$0.0065 from its previous closing price. On the day, 2002142 shares were traded.
Ratios:
Our analysis of NBY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.67. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on September 18, 2019, initiated with a Buy rating and assigned the stock a target price of $1.10.
On July 06, 2018, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $4.
Laidlaw reiterated its Buy rating for the stock on November 15, 2017, while the target price for the stock was revised from $10 to $8.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBY now has a Market Capitalization of 3.15M and an Enterprise Value of 4.66M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.21 while its Price-to-Book (P/B) ratio in mrq is 0.86. Its current Enterprise Value per Revenue stands at 0.32 whereas that against EBITDA is -0.70.
Stock Price History:
Over the past 52 weeks, NBY has reached a high of $1.95, while it has fallen to a 52-week low of $0.10. The 50-Day Moving Average of the stock is 0.1464, while the 200-Day Moving Average is calculated to be 0.3967.
Shares Statistics:
NBY traded an average of 3.61M shares per day over the past three months and 2.85M shares per day over the past ten days. A total of 30.10M shares are outstanding, with a floating share count of 29.36M. Insiders hold about 2.44% of the company’s shares, while institutions hold 3.95% stake in the company. Shares short for NBY as of Mar 15, 2024 were 116.07k with a Short Ratio of 0.03, compared to 302.42k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.39% and a Short% of Float of 0.39%.
Earnings Estimates
The firm’s stock currently is rated by 1 analysts. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.2, while EPS last year was -$0.85. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.2 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.73 and -$0.73 for the fiscal current year, implying an average EPS of -$0.73. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $4M to a low estimate of $4M. As of the current estimate, Novabay Pharmaceuticals Inc’s year-ago sales were $3.2M, an estimated increase of 25.00% from the year-ago figure.
A total of 1 analysts have provided revenue estimates for NBY’s current fiscal year. The highest revenue estimate was $16M, while the lowest revenue estimate was $16M, resulting in an average revenue estimate of $16M. In the same quarter a year ago, actual revenue was $14.73M, up 8.70% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $22.36M in the next fiscal year. The high estimate is $22.36M and the low estimate is $22.36M. The average revenue growth estimate for next year is up 39.80% from the average revenue estimate for this year.
